HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Guest Access | Sign In via User Name/Password

This Article Full Text Free Full Text (PDF) Free Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (16) Citing Articles via Google Scholar Google Scholar Articles by Field, S. K. Articles by Cowie, R. L. Search for Related Content PubMed PubMed Citation Articles by Field, S. K. Articles by Cowie, R. L.

Treatment of Mycobacterium avium-intracellulare complex Lung Disease With a Macrolide, Ethambutol, and Clofazimine^*

^* From the Division of Respiratory Medicine University of Calgary Medical School and Calgary Health Region Tuberculosis Services, Calgary, AB, Canada.

Correspondence to: Stephen K. Field, MD, CM, FCCP, Foothills Hospital, 1403 29th St NW Calgary, AB, Canada T2N 2T9; e-mail sfield{at}ucalgary.ca

Background: Mycobacterium avium-intracellulare (MAC) causes progressive lung disease. Recommended treatment regimens include a macrolide and a rifamycin, but drug intolerance and relapse after treatment is completed often limit successful therapy.

Methods: Consecutive individuals referred for treatment of MAC lung disease were treated with a regimen that included either clarithromycin, 500 mg bid, or azithromycin, 250 mg/d, on weekdays; ethambutol, 15 mg/kg/d; and clofazimine, 100 mg/d. The intention was to treat patients for a minimum of 12 months. The diagnosis of MAC lung disease was confirmed by multiple positive sputum culture findings in patients with typical symptoms and radiologic findings.

Results: Thirty patients (27 women and 3 men; mean age, 70 ± 9.4 years [SD]) were treated. A total of 22 of the patients reported adverse effects from clarithromycin or azithromycin. Intolerance of clarithromycin resulted in the withdrawal of four patients before sputum conversion. The remaining patients continued treatment for an average of 10 months, and sputum findings converted to negative in all 26 patients (87%). One patient died of unrelated causes while still receiving therapy, and five patients (19%) relapsed an average of 17 months after treatment was completed.

Conclusions: Treatment with a macrolide, ethambutol, and clofazimine was successful in 20 of 30 patients (67%) with MAC lung disease and is a reasonable alternative to rifamycin-containing regimens.

Key Words: azithromycin • bronchiectasis • clarithromycin • clofazimine • ethambutol • Mycobacterium avium

This article has been cited by other articles:

				J. Glassroth Pulmonary Disease Due to Nontuberculous Mycobacteria Chest, January 1, 2008; 133(1): 243 - 251. [Abstract] [Full Text] [PDF]

				D. E. Griffith, B. A. Brown-Elliott, B. Langsjoen, Y. Zhang, X. Pan, W. Girard, K. Nelson, J. Caccitolo, J. Alvarez, S. Shepherd, et al. Clinical and Molecular Analysis of Macrolide Resistance in Mycobacterium avium Complex Lung Disease Am. J. Respir. Crit. Care Med., October 15, 2006; 174(8): 928 - 934. [Abstract] [Full Text] [PDF]

				W.-J. Koh, O. J. Kwon, E. J. Kim, K. S. Lee, C.-S. Ki, and J. W. Kim NRAMP1 Gene Polymorphism and Susceptibility to Nontuberculous Mycobacterial Lung Diseases Chest, July 1, 2005; 128(1): 94 - 101. [Abstract] [Full Text] [PDF]

				Y. Shiraishi, Y. Nakajima, N. Katsuragi, M. Kurai, and N. Takahashi Pneumonectomy for nontuberculous mycobacterial infections Ann. Thorac. Surg., August 1, 2004; 78(2): 399 - 403. [Abstract] [Full Text] [PDF]